The Federal Circuit has upheld decisions by the Patent Trial and Appeal Board (PTAB) that invalidated all claims in two patents held by Agilent Technologies concerning CRISPR, a widely used gene-editing technology. This decision represents a significant victory for Synthego Corp., which had faced allegations of infringing these patents. The ruling confirms the PTAB’s findings that the patent claims were not sustainable under scrutiny.
CRISPR, an essential tool in gene editing, has been the center of numerous patent disputes as companies aim to secure intellectual property rights for its various applications. The Federal Circuit’s decision in favor of the PTAB’s earlier judgments reinforces the board’s stance and sets a precedent in the ongoing legal conversations around CRISPR technology.
To explore more details regarding the Federal Circuit’s affirmation and its implications for both companies, the original article provides an in-depth review of the case developments.